Northern Trust’s Xeris Biopharma Holdings XERS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.38M | Buy |
1,444,617
+57,788
| +4% | +$383K | ﹤0.01% | 2170 |
|
|
2025
Q4 | $10.9M | Buy |
1,386,829
+23,700
| +2% | +$187K | ﹤0.01% | 2037 |
|
|
2025
Q3 | $11.1M | Buy |
1,363,129
+69,599
| +5% | +$462K | ﹤0.01% | 2053 |
|
|
2025
Q2 | $6.04M | Buy |
1,293,530
+92,330
| +8% | +$423K | ﹤0.01% | 2359 |
|
|
2025
Q1 | $6.59M | Buy |
1,201,200
+4,819
| +0.4% | +$19.5K | ﹤0.01% | 2273 |
|
|
2024
Q4 | $4.06M | Buy |
1,196,381
+38,155
| +3% | +$123K | ﹤0.01% | 2630 |
|
|
2024
Q3 | $3.3M | Buy |
1,158,226
+51,057
| +5% | +$131K | ﹤0.01% | 2709 |
|
|
2024
Q2 | $2.49M | Sell |
1,107,169
-52,386
| -5% | -$106K | ﹤0.01% | 2780 |
|
|
2024
Q1 | $2.56M | Sell |
1,159,555
-5,808
| -0.5% | -$15K | ﹤0.01% | 2835 |
|
|
2023
Q4 | $2.74M | Buy |
1,165,363
+20,146
| +2% | +$37.2K | ﹤0.01% | 2821 |
|
|
2023
Q3 | $2.13M | Sell |
1,145,217
-8,566
| -0.7% | -$19.6K | ﹤0.01% | 2900 |
|
|
2023
Q2 | $3.02M | Buy |
1,153,783
+44,206
| +4% | +$113K | ﹤0.01% | 2779 |
|
|
2023
Q1 | $1.81M | Buy |
1,109,577
+13,205
| +1% | +$16.5K | ﹤0.01% | 2987 |
|
|
2022
Q4 | $1.46M | Buy |
1,096,372
+1,749
| +0.2% | +$2.47K | ﹤0.01% | 3138 |
|
|
2022
Q3 | $1.71M | Sell |
1,094,623
-10,311
| -0.9% | -$17.1K | ﹤0.01% | 3104 |
|
|
2022
Q2 | $1.7M | Buy |
1,104,934
+898,486
| +435% | +$1.9M | ﹤0.01% | 3146 |
|
|
2022
Q1 | $529K | Buy |
206,448
+16,426
| +9% | +$40.1K | ﹤0.01% | 3715 |
|
|
2021
Q4 | $557K | Buy |
190,022
+67,263
| +55% | +$145K | ﹤0.01% | 3767 |
|
|
2021
Q3 | $301K | Sell |
122,759
-4,179
| -3% | -$12.1K | ﹤0.01% | 3981 |
|
|
2021
Q2 | $517K | Sell |
126,938
-365,760
| -74% | -$1.4M | ﹤0.01% | 3694 |
|
|
2021
Q1 | $2.22M | Buy |
492,698
+5,342
| +1% | +$28.8K | ﹤0.01% | 3188 |
|
|
2020
Q4 | $2.4M | Sell |
487,356
-22,688
| -4% | -$114K | ﹤0.01% | 3107 |
|
|
2020
Q3 | $3.02M | Buy |
510,044
+99,891
| +24% | +$399K | ﹤0.01% | 2838 |
|
|
2020
Q2 | $1.09M | Buy |
410,153
+11,304
| +3% | +$39.4K | ﹤0.01% | 3322 |
|
|
2020
Q1 | $778K | Buy |
398,849
+96,675
| +32% | +$416K | ﹤0.01% | 3318 |
|
|
2019
Q4 | $2.13M | Sell |
302,174
-3,674
| -1% | -$30.3K | ﹤0.01% | 3098 |
|
|
2019
Q3 | $3.01M | Buy |
305,848
+56,634
| +23% | +$636K | ﹤0.01% | 2859 |
|
|
2019
Q2 | $2.85M | Buy |
249,214
+9,188
| +4% | +$96.5K | ﹤0.01% | 2865 |
|
|
2019
Q1 | $2.41M | Buy |
240,026
+165,603
| +223% | +$2.12M | ﹤0.01% | 2958 |
|
|
2018
Q4 | $1.26M | Buy |
74,423
+1,089
| +1% | +$21.8K | ﹤0.01% | 3277 |
|
|
2018
Q3 | $1.29M | Buy |
+73,334
| New | +$1.59M | ﹤0.01% | 3397 |
|
Other funds holding XERS
VCM
RA
N
VPM
Northern Trust's XERS Position: Q1 2026 in Review
Northern Trust increased its Xeris Biopharma Holdings (XERS) stake by 4.2% in Q1 2026, buying an estimated $383K and bringing the position to 1,444,617 shares worth $8.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2170.
Northern Trust first reported a position in XERS in Q3 2018 and has held it in 31 quarters since. The position peaked at $11.1M in Q3 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.
- Northern Trust held 1,444,617 shares of Xeris Biopharma Holdings worth $8.38M as of Q1 2026.
- Northern Trust bought 57,788 Xeris Biopharma Holdings shares in Q1 2026, an estimated $383K.
- Xeris Biopharma Holdings made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2170 holding.
- Northern Trust first reported a position in Xeris Biopharma Holdings in Q3 2018 and has held it in 31 quarters since.
- Northern Trust's Xeris Biopharma Holdings position peaked at $11.1M in Q3 2025.
- 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.